Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Coherus Biosciences Inc Market Cap
From what 8 stock analysts predict, the share price for Coherus Biosciences Inc (CHRS) might increase by 432.79% in the next year. This is based on a 12-month average estimation for CHRS. Price targets go from $1.5 to $12. The majority of stock analysts believe CHRS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
CHRS is a stock in Healthcare which has been forecasted to be worth $6.5 as an average. On the higher end, the forecast price is $12 USD by Robyn Karnauskas from Truist Securities and on the lower end CHRS is forecasted to be $1.5 by Ashwani Verma from UBS.
These are the latest 20 analyst ratings of CHRS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Colleen Kusy Baird | Outperform | $4 | Maintains | Nov 8, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $12 | Reiterates | Nov 7, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $12 | Reiterates | Sep 16, 2024 |
| Ashwani Verma UBS | Neutral | $1.5 | Downgrade | Aug 16, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $12 | Reiterates | Aug 5, 2024 |
| Colleen Kusy Baird | Outperform | $8 | Maintains | Jul 1, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $12 | Reiterates | May 24, 2024 |
| Robyn Karnauskas Truist Securities | Buy | $7 | Maintains | May 13, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $12 | Maintains | May 10, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $11 | Maintains | Mar 20, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $13 | Reiterates | Mar 14, 2024 |
| Robyn Karnauskas Truist Securities | Buy | $8 | Maintains | Jan 23, 2024 |
| Colleen Kusy Baird | Outperform | $9 | Maintains | Jan 23, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $13 | Reiterates | Dec 27, 2023 |
| Douglas Tsao HC Wainwright & Co. | Buy | $13 | Reiterates | Dec 7, 2023 |
| Robyn Karnauskas Truist Securities | Buy | $12 | Reiterates | Nov 28, 2023 |
| Colleen Kusy Baird | Outperform | $11 | Initiates | Nov 17, 2023 |
| Jason McCarthy Maxim Group | Hold | Downgrade | Nov 8, 2023 | |
| Douglas Tsao HC Wainwright & Co. | Buy | $13 | Maintains | Nov 7, 2023 |
| Balaji Prasad Barclays | Overweight | $7 | Maintains | Oct 23, 2023 |
When did it IPO
2014
Staff Count
235
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Dennis M. Lanfear
Market Cap
$140.6M
In 2023, CHRS generated $257.2M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CHRS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 27 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Coherus BioSciences, Inc. (NASDAQ: CHRS) will participate in the 2024 Citi Global Healthcare Conference, with CDO Dr. Theresa LaVallee on the oncology panel on December 3, 2024.
Why It Matters - Coherus BioSciences’ participation in the Citi Global Healthcare Conference highlights its commitment to oncology innovation, potentially boosting investor confidence and interest in its future growth.
Wed, 06 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Coherus BioSciences, Inc. (CHRS) held its Q3 2024 earnings call, discussing financial performance and future outlook. Details on revenue and key developments were provided.
Why It Matters - The Q3 2024 earnings call for Coherus BioSciences provides insights into financial performance, future guidance, and strategic direction, influencing investment decisions and market perception of the company.
Wed, 06 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Q3 2024 net revenue reached $70.8 million, boosted by a 30% quarter-over-quarter increase in UDENYCA® net revenue.
Why It Matters - A 30% increase in UDENYCA® net revenue indicates strong product performance, suggesting potential for continued growth and profitability, which can positively impact stock valuation.
Wed, 06 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Coherus BioSciences (CHRS) reported a Q3 loss of $0.01 per share, better than the expected loss of $0.10 and an improvement from a loss of $0.27 per share a year prior.
Why It Matters - Coherus BioSciences' smaller loss than expected indicates improved financial performance, potentially boosting investor confidence and affecting stock valuation positively.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Coherus BioSciences, Inc. (NASDAQ: CHRS) will release Q3 2024 financial results on November 6, 2024, after market close, followed by a conference call at 5:00 p.m. ET.
Why It Matters - Coherus BioSciences' upcoming financial results announcement and conference call could impact stock performance, influencing investor sentiment and market expectations for the company.
Tue, 13 Aug 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Coherus BioSciences focuses on biosimilars, notably UDENYCA, which holds a 29% market share. Strategic divestitures may affect its financial position after Q3 2024.
Why It Matters - Coherus BioSciences' focus on profitable biosimilars and strong revenue from UDENYCA, along with strategic divestitures, indicates potential growth and financial stability, influencing stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
